文献速递炎症性肠病

Efmarodocokin Alfa(一种白介素-22激动剂)对比维多珠单抗治疗溃疡性结肠炎患者的随机II期研究

A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-16

这项随机II期研究比较了3种剂量Efmarodocokin Alfa(每4周静脉给药30、60、90 μg/kg)、安慰剂及维多珠单抗治疗中重度溃疡性结肠炎的疗效。第8周时Efmarodocokin Alfa各剂量组临床缓解率分别为12%、9%、12%,安慰剂组9%、维多珠单抗组26%,Efmarodocokin Alfa未显示优于安慰剂的疗效,研究因无效提前终止,但观察到药效学标志物呈剂量依赖性升高。

要点

  • Efmarodocokin Alfa 30、60、90 μg/kg组第8周临床缓解率分别为12%、9%、12%,安慰剂组9%,维多珠单抗组26%。
  • 第8周内镜愈合率在Efmarodocokin Alfa 30、60、90 μg/kg组分别为14%、14%、12%,安慰剂组14%,维多珠单抗组33%。
  • Efmarodocokin Alfa未显示优于安慰剂的疗效,II期研究因无效提前终止,但观察到靶点结合证据。

核心结论

  • Efmarodocokin Alfa未显示优于安慰剂的疗效,该II期研究因无效提前终止,但存在靶点结合证据(皮肤不良事件、再生胰岛衍生蛋白3-alpha水平)。

研究设计与样本

  • 随机II期试验,纳入中重度溃疡性结肠炎患者,比较Efmarodocokin Alfa 30 μg/kg(n=43)、60 μg/kg(n=44)、90 μg/kg(n=43)每4周静脉给药与安慰剂(n=22)及维多珠单抗(n=43)。

主要发现

  • 第8周临床缓解率:Efmarodocokin Alfa 30、60、90 μg/kg组分别为12%、9%、12%,安慰剂组9%,维多珠单抗组26%。
  • 第8周内镜愈合率:Efmarodocokin Alfa 30、60、90 μg/kg组分别为14%、14%、12%,安慰剂组14%,维多珠单抗组33%。
  • Efmarodocokin Alfa各剂量组在临床缓解、临床应答、内镜愈合或内镜缓解方面较安慰剂均未显示统计学显著改善,维多珠单抗显示一定疗效。
  • 观察到药效学标志物(再生胰岛衍生蛋白3-alpha和C反应蛋白水平)呈剂量依赖性升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该II期研究因无效提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Efmarodocokin alfa is an interleukin (IL)-22 agonist, with favorable pharmacokinetic properties and an acceptable safety profile. This study further explored the therapeutic potential of efmarodocokin alfa compared with vedolizumab in patients with ulcerative colitis (UC). METHODS: This randomized phase II trial evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of 3 doses of efmarodocokin alfa administered intravenously every 4 weeks (30 μg/kg [n = 43], 60 μg/kg [n = 44], and 90 μg/kg [n = 43]) compared with placebo (n = 22) and with vedolizumab (n = 43) in the treatment of moderate to severe UC. Key clinical outcomes were assessed through the modified Mayo Clinic Score, and endoscopic evaluations by a central reader. RESULTS: Efmarodocokin alfa was adequately tolerated with an acceptable safety profile. Although efmarodocokin alfa did not show statistically significant improvement in clinical remission, clinical response, endoscopic healing, or endoscopic remission at week 8 compared with placebo, vedolizumab demonstrated some efficacy. Clinical remission was achieved by 12%, 9%, and 12% of patients in the 30, 60, and 90 μg/kg dose arms, respectively, compared with 9% and 26% of patients in the placebo and vedolizumab arms at week 8. Similarly, endoscopic healing at week 8 was achieved by 14%, 14%, and 12% of patients in the 30, 60, and 90 μg/kg dose arms, respectively, compared with 14% and 33% of patients in the placebo and vedolizumab arms. A dose-dependent increase in pharmacodynamic biomarkers was observed (regenerating islet-derived protein 3-alpha and C-reactive protein levels). CONCLUSION: Efmarodocokin alfa did not demonstrate efficacy compared with placebo, and this phase II study was ended early for futility; however, there was evidence of target engagement (skin adverse events, regenerating islet-derived protein 3-alpha levels). CLINICALTRIALS: gov, Number: NCT03558152.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Danese S, Rothenberg ME, Lim JJ, et al. A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2024. PMID: 39694207. doi:10.1016/j.cgh.2024.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。